Source: Medscape, June 2025
TOPLINE:
Patients with amelanotic melanoma showed poorer disease-specific survival (DSS) than those with melanotic melanoma in a Surveillance, Epidemiology, and End Results (SEER) database analysis.
METHODOLOGY:
- Researchers analyzed data on patients with invasive cutaneous amelanotic melanoma (n = 1598) and melanotic melanoma (n = 417,974) from the SEER 17 database between 2000 and 2021.
- Patients with amelanotic melanoma were older at diagnosis and presented with more advanced-stage disease than those with melanotic melanoma (regional/distant stages: 26.8% vs 12.4%), ulceration (35.6% vs 13.1%), and Breslow thickness > 2 mm (42% vs 17%).